Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The dilution related to the share registration has been known for many months, ever since the LPC funding was announced. It's not new news. There will be dilution as the company draws on additional funds per the agreement, but it doesn't happen all at once. It's entirely possible the full $20M in funding won't be needed if/when sources such as grants, partnership payments, and LymPro revenues are available to fund the company's operations. The dilution from this funding may be less than expected if any of these sources replace the funds needed.
I suppose it might cause concern to shareholders who don't understand the difference between the previous registration statement and the effectiveness statement, believing there is more dilution than what is actually planned. We saw this confusion in the past. Hopefully now most longs understand it, and it shouldn't matter much to the flippers. Still, some may try to instill dilution fears into shareholders who are unfamiliar with the purpose of these filings.
To Orion1983: Us? You are no longer a shareholder, as per your recent posts, correct? The TBI connection is an ongoing thing. The company is involved with partners who are bringing more attention to the issue. Governments, corporations and even colleges/high schools are getting involved. What exactly is your concern? The company is aligning themselves and developing strategic partnerships to be a part of the solution. This doesn't happen overnight. Neither does success for the company and as a shareholder in the investment. I've been a shareholder for less than 2 years, and I am very happy with the company progress during that time, and my investment gains. I fully expect those gains to be orders of magnitude greater over the coming years, and likely the best investment I've ever made. Obviously I don't share your concerns over the company's efforts in TBI. Nice to see all of these concerns posted while being out of the stock. Suspicious, to say the least.
Probably the same precedent that was used to make the statement that there will be little to no market for LymPro. Seems the medical community and the company advisors disagree. We'll see who is right soon enough. Backpedaling by some is to be expected and encouraged. Will be very entertaining.
MJFF is firm with their notion that Eltoprazine is a very promising treatment for dyskinesia associated with long-term use of Levadopa in treating PD.
Good to know. I'll set a sell target price in-between #2 and #3 at about $20 per share, creating a profit of $140MM on my AMBS investment, with $120MM of that in my Roth, never to be taxed (beyond the $73K I'm paying this year in taxes).
Thanks for the strong support of the company and for confirming the superb outlook of my investment here. Much appreciated.
Since that trial wasn't originally initiated as a retrospective study, the biases you've claimed related to that type of study shouldn't be present. While it is retrospective in the sense it is looking back at known data, the fact those biases aren't present should give significant value to the data generated.
It is clear the original trial in 2005 was a prospective study. The current study is certainly retrospective as it is not generating new data but looking back at data already existing from the original trial and the outcomes of the trial subjects over the years.
By the way, I don't agree with your statement:
NASDAQ or AMEX?
My vote is Amarantus uplisting to the NASDAQ Capital Market.
2014. Sooner rather than later.
Don't miss it.
joboggi, you stated, "we know how PD is caused."
The MJFF website states:
This is an amendment to the previous S-1 filing of 5/14 (hence, the S-1/A) and not a new offering in addition to the previous registration statement. So it's not pushing the company close to the 1 billion authorized share limit, and therefore will not require an increase in authorized shares. As previously reported, this provides funding for company operations through 2015, where revenues from LymPro commercialization will provide funding necessary to move the company forward on development of their other assets at that point. I don't anticipate an increase in authorized shares after revenues begin to come into the company.
This offering doesn't result in an immediate increase to the number of shares indicated below. This simply authorizes the specified number of shares so they may be sold to LPC per their agreement as additional capital is needed by the company.
orion, I don't agree with the belief that LymPro was so cheap because there is no demand for the test. From statements made by Gerald, Dr. Lowe, and Dr. Simon, there are indications of significant demand for the test in both AD research and medical practice.
As for the real reasons why Amarantus was able to acquire LymPro so cheaply, the most complete discussion was given by Gerald himself in response to a question by Jason Napadano in the April 2013 investor conference call. There was up-front cash and shares, there is a milestone payment of $1MM, and there are 9% royalties going to MemoryDX upon commercialization. The acquisition is structured so Amarantus funds the commercialization and MemoryDX receives a percentage of the profits. In that regard, it's not as "cheap" as it seems. This is a significant amount of money going to MemoryDX if actual demand for the test reaches revenue estimates.
Here's a link to that discussion. It answers a lot of questions and dispels some false assumptions.
LymPro Acquisition
Does anyone have the April 2013 Conference Call audio files I posted to the board? I posted 2 versions, MP3 and AAC (M4A/M4B). I no longer have the files and there's a key piece of discussion regarding LymPro acquisition in that file I would like to have.
Please let me know if you still have either of these audio files. They should be around 32MB in size, and therefore may be too large to email. We can set up some means of data transfer (DropBox, file sharing, etc) if email is not an option.
Note: These files are from the 2013 shareholder conference call on April 16, 2013, not the recent 2014 call.
Thanks.
I agree, all the ducks are lined up for something major. As long as it happens before October... I have a $73K tax bill to pay on a Roth conversion of 6.8 million AMBS shares. Would love to see $1 per share by then, so I only pay 1% of the value of my Amarantus investment in taxes. $0.50 would be okay too, only paying 2% in taxes. What will those shares be worth in 5 years? God only knows. And think of how many patients will have been helped by then.
We know Gerald has a number of significant milestones to announce before then. Anxious to see who the LymPro partner is and what effect that announcement has on the share price. Also looking forward to the revenue estimates in July after the consultations with various medical groups and research labs. In this regard, Spock might say, "The needs of the many outweigh the opinion of the one."
We can not only see all these ducks lined up, but we can hear them as well. Can you hear the "Quack, quack, quack" of all these ducks lined up in a row?
Long and strong Amarantus.
That sticky is not only outdated, but it was wrong from the moment it was posted. My most blatant lie is:
joboggi, how do you come to make this statement?
NASDAQ also has a $2 up-list option. I covered this under a previous post.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=99246321
Claims that a reverse split is required to uplist are pure speculation and guessing. No one knows what will unfold between now and then or how the market will react to the news. For anyone to claim that a RS will be required to uplist is totally ludicrous at this point. There is no doubt about that.
Thanks barcode, for going above and beyond the call in your efforts to obtain those documents from NIH. Those letters clearly show there's interest in LymPro, even in the early stages, despite the self-proclaimed expert's claim. Hard to believe all these high-profile new hires, and even the companies who expressed interest in those letters have it all wrong. I suppose when a commercialization partner is announced, they'll have it wrong as well. LOL I think we all understand who is right and who is wrong on the topic of LymPro demand in the medical community.
The opinion that LymPro is worthless or has very limited value in the medical community is about as believable as this elephant.
More garbage facts supported by virtually no research. You posted:
Is this the same top MJFF biomarker physician who was NOT part of the MJF interview on Letterman? Yet his comments were somehow presented as evidence of what MJF said on this interview?
Ridiculously funny logic.
I didn't say we were countering with actual science. The science you link to has little to do with your claims in many cases.
Still waiting for the link to reports of serious side effects with Eltoprazine. Dr. Lowe states it has a strong safety profile, yet you continue to maintain it doesn't.
Where's the proof, Mr. Expert?
Take what chance? I'm just asking for links to proof of the claimed serious side effects. You provide plenty of links for other things. Why not this?
Instead, all we get are cryptic responses. Such responses seriously diminish any respectability you seek.
Some of us actually try to counter unsubstantiated claims regarding the company and their science. That should not be interpreted as placing any level of importance or respect on those posts. Quite the contrary.
Perhaps we should all do as you suggest, and put you back on ignore. Then you can return to responding to your own posts. LMAO
You provide plenty of links that have little or no impact on the claims you are making... too many side effects for Eltoprazine, for instance, but when pushed to provide actual supporting evidence, you say we should look it up ourselves.
I imagine that's because there is no supporting evidence.
Well, there are those who actually do biotech, and there are those who only write about it.
Personally, I tend to favor the people doing the hands on work as the experts who know what's really going on.
I don't believe anyone here agrees with your assessment that Jason identified himself as a pumper, any more than they agree with your assessment on anything else.
Where's the proof to back up your claim that Eltoprazine has too many serious side effects? It's funny how Dr. Lowe keeps presenting the strong safety profile as a key factor in their plans to move forward with clinical trials. Do you believe Dr. Lowe is lying? Show us some proof. Show us some studies that report on the serious side effects of Eltoprazine.
There have been numerous articles published and linked here that describe the large demand for an AD blood test like LymPro, not only in the AD research community, but also in general practice. So it would seem the rest of the medical community doesn't agree with your opinion that there will be little to no market for this blood test. I seriously doubt the Amarantus team would be pursuing this market, nor would their advisors be guiding them in this endeavor, if there wasn't a substantial market for LymPro. What expertise in this area do you have that would lead us to believe your opinion regarding LymPro is more accurate than these highly respected experts in the field?
Regarding your claim that LymPro has already been leap-frogged, please provide proof of this, as well as when this superior product is expected to enter the commercial market. But if you really believe LymPro has little to no market demand, then why would it matter if someone else had leap-frogged them? Your attempts to spread doubt about LymPro are conflicting.
Regarding your reference to the SA article claiming 800,000,000 shares in the float, the latest annual filing stated:
I'm not signing up on Medscape so I can read the article you linked to, which doesn't link to the article.
We were discussion your inaccurate statement about what MJF stated on Letterman. He did NOT say what you claimed.
You asked me what biomarker was close for PD. Again, that wasn't part of the discussion about your inaccurate accounting of the MJF interview.
You reported inaccurately concerning the interview. End of story. We may not be close to a biomarker for PD, but MJF didn't say that on the interview. No amount of other evidence you dig up is going to change that.
You didn't answer my question on Eltoprazine. Do you think Dr. Lowe doesn't know what he's talking about regarding serious side effects for the drug, or is he lying to shareholders?
Ok, so you agree he didn't say anything about a biomarker test for PD not being close?
How about at least trying to report accurately what you saw or heard? That would be a great start.
Perhaps just listening to the audio portion without the visual distraction will help.
MJF Interview
I thought he sounded pretty upbeat on the research being done. He mentioned having evaluated 600 drug candidates and conducted over 60 trials. He mentioned that science is hard, but didn't sound either desperate or negative about their work.
And according to the Amarantus Development Pipeline, NuroPro is ready for Phase II testing. Hopefully we'll see some progress on NuroPro now that we have additional people working on the diagnostics front, as well as the new round of funding to help pay for it. Revenues from LymPro should really start to accelerate things in the pipeline currently in lower priority status.
Was your friend dissatisfied with the conference call? It seems that most investors here who have reported in felt pretty good about it. I'm reminded of a recent tweet by Gerald.
My pleasure, Risk. I will say you were very well spoken in your questions and it's clear you put some thought into them ahead of time. I was glad to learn more about the CLIA process as it impacts LymPro commercialization. Of course, our resident non-Doc continues to believe no one will want this test since there's no cure. Amazing how Dr. Lowe and all these new hires believe exactly the opposite. LOL
I think you'll agree the quality of the new audio files are much better than the previous versions. The number of artifacts that cropped up in the last third of the previous versions were really annoying.
The call certainly gives one the sense that's it's not a matter of IF, but WHEN. I'm hanging in no matter how long it takes.
I loved the last caller who wanted to know what the stock price was going to be in June. LOL Wouldn't we all like to know that. He was clearly a trader, or someone wanting some guidance whether he should buy shares now or buy them later.
I checked the DTCC List of OTC Cleared Securities again today and found no mention of AMBS for adding the 'E' to the ticker symbol. There are a number of other companies on the list who filed late. I know we all read Gerald's tweet and it suggested we had received some additional grace period due to the near-term CFO change. I've been checking the DTCC updates this week to ensure this was the case.
All seems A-OK on the late-filing status. I realize some will think I'm stating the obvious, but I posted earlier in the week about the listing and I wanted to follow up.
http://www.dtcc.com/legal/important-notices.aspx?q=OTC+Cleared+Securities+Updates&pgs=1
NT, would you mind replacing the stickied audio file post with the newer one? I wasn't happy with the number of artifacts present in the initial version that I streamed in real time through Google Voice. I captured the archived version today and found it to be free of most of the artifacts present in the previous version. The new audio files are clearer, but have the same content and chapters.
The download links in the previous post no longer work as those files have been deleted.
Thanks.
Amarantus April 2014 Conference Call audio files
I've just updated the audio files with a clearer version. The archived call version didn't have most the artifacts present in the live version. If you want the clearer version use the links below. The old files have been removed.
The AAC version includes bookmarks for direct access to specific topics, and is the recommended version if you have iTunes/iPod or software/player that handles the AAC or M4A audio format.
The MP3 version doesn't support bookmarks. You can use the Topic listing info to manually advance the playback to the time of the desired topic. Click the link to view the Topics. Right-click the link to download the PNG image file.
Topics List
AAC version
MP3 version
Can one of the moderators sticky the audio file post and replace my stickied post on uplisting? I don't know which moderator stickied that post so I don't know who to ask to remove or replace it. Thanks.
My posting of the audio files will be a little late. I had trouble logging in and it took awhile for the operator to get me connected. The passcode I entered from the press release didn't seem to work.
I missed the first 5-7 minutes of the call, but captured the rest of it. As soon as the archive is posted, I'll recapture the missing part and upload the complete audio files. The files I'm building are mainly for reference, with bookmarks to key areas to enable investors to go back later and review specific parts.
I was told the replay archive is typically available a few hours after the call. I'll get the files posted as soon as I get the part I missed.
Conference Call Information
Management will host a conference call on Thursday, April 24, 2014 at 4:05 PM ET to provide updates and address investor questions regarding general business developments. Participants will include President & CEO Gerald Commissiong, Dr. David Lowe and Bob Farrell, CFO.
Interested parties may participate by dialing 877-737-7051, (International): 201-689-8878 and entering pass code 2027916 approximately five minutes before the call start time.
A replay of the call will be available by dialing 1-877-660-6853 (International): 201-612-7415 and entering conference ID number 13580388.
http://ir.stockpr.com/amarantus/company-news/detail/1224/amarantus-announces-2013-year-end-financial-results
I will post investor conference call audio files to the board tomorrow evening, so listeners can go directly to specific parts they want to review without having to dial the number and listen to the entire hour-long call again.
Like last year, I will create 2 versions (AAC and MP3). The AAC version will have the topic markers built in. The MP3 version will include a listing of times for manually accessing each topic. These files are for download and playback on your computer or phone, not streaming audio from the server. You can already get that by dialing the phone number in the press release.
Perhaps some will find these files useful.
Your link was messed up. Here's the same link that works.
http://opportunistmagazine.com/gerald-commissiong-name/
Okay, that seems to indicate we had some leeway. I only posted Gerald's response, but failed to consider the question he was asked.
Thanks for the clarification. Perhaps all the concern and freaking out over the late filing was for nothing.
As some have stated: "You're not late, until you're late." So far, it doesn't appear we were late in the regulatory sense, and that's all that matters.